G. Piaggio, D. Elbourne, D. Altman, S. Pocock, and S. Evans, Reporting of Noninferiority and Equivalence Randomized Trials, JAMA, vol.295, issue.10, pp.1152-1160, 2006.
DOI : 10.1001/jama.295.10.1152

R. Temple and S. Ellenberg, Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues, Annals of Internal Medicine, vol.133, issue.6, pp.455-463, 2000.
DOI : 10.7326/0003-4819-133-6-200009190-00014

B. Djulbegovic and M. Clarke, Scientific and Ethical Issues in Equivalence Trials, JAMA, vol.285, issue.9, pp.1206-1208, 2001.
DOI : 10.1001/jama.285.9.1206

S. Staszewski, J. Morales-ramirez, K. Tashima, A. Rachlis, D. Skiest et al., Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults, New England Journal of Medicine, vol.341, issue.25
DOI : 10.1056/NEJM199912163412501

S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall et al., Lopinavir???Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection, New England Journal of Medicine, vol.346, issue.26, pp.2039-2046, 2002.
DOI : 10.1056/NEJMoa012354

B. Kirshner, Methodological standards for assessing therapeutic equivalence, Journal of Clinical Epidemiology, vol.44, issue.8, pp.839-849, 1991.
DOI : 10.1016/0895-4356(91)90139-Z

B. Jones, P. Jarvis, J. Lewis, and A. Ebbutt, Trials to assess equivalence: the importance of rigorous methods, BMJ, vol.313, issue.7048, pp.36-39, 1996.
DOI : 10.1136/bmj.313.7048.36

F. Mcalister and D. Sackett, Active-control equivalence trials and antihypertensive agents, The American Journal of Medicine, vol.111, issue.7, pp.553-558, 2001.
DOI : 10.1016/S0002-9343(01)00900-7

S. Staszewski, P. Keiser, J. Montaner, F. Raffi, J. Gathe et al., Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>, JAMA, vol.285, issue.9, pp.1155-1163, 2001.
DOI : 10.1001/jama.285.9.1155

E. Martinez, J. Arnaiz, D. Podzamczer, D. Dalmau, E. Ribera et al., Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection, New England Journal of Medicine, vol.349, issue.11, pp.1036-1046, 2003.
DOI : 10.1056/NEJMoa021589

J. Arnaiz, J. Mallolas, D. Podzamczer, J. Gerstoft, J. Lundgren et al., Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load, AIDS, vol.17, issue.6, pp.831-840, 2003.
DOI : 10.1097/00002030-200304110-00008

F. Van-leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller et al., Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study, The Lancet, vol.363, issue.9417, pp.1253-1263, 2004.
DOI : 10.1016/S0140-6736(04)15997-7

J. Gallant, S. Staszewski, A. Pozniak, E. Dejesus, J. Suleiman et al., Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients<SUBTITLE>A 3-Year Randomized Trial</SUBTITLE>, JAMA, vol.292, issue.2, pp.191-201, 2004.
DOI : 10.1001/jama.292.2.191

J. Gathe, P. Ive, R. Wood, D. Schurmann, N. Bellos et al., SOLO, AIDS, vol.18, issue.11, pp.1529-1537, 2004.
DOI : 10.1097/01.aids.0000131332.30548.92

C. Benson, C. Van-der-horst, A. Lamarca, D. Haas, C. Mcdonald et al., A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV, AIDS, vol.18, issue.17, pp.2269-2276, 2004.
DOI : 10.1097/00002030-200411190-00007

E. Dejesus, D. Mccarty, C. Farthing, D. Shortino, B. Grinsztejn et al., Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial, Clinical Infectious Diseases, vol.39, issue.3, pp.411-418, 2004.
DOI : 10.1086/422143

J. Molina, V. Journot, M. , L. Yeni, P. Rozenbaum et al., Simplification Therapy with Once???Daily Emtricitabine, Didanosine, and Efavirenz in HIV???1???Infected Adults with Viral Suppression Receiving a Protease Inhibitor???Based Regimen: A Randomized Trial, The Journal of Infectious Diseases, vol.191, issue.6, pp.830-839, 2005.
DOI : 10.1086/428091

E. Dejesus, G. Herrera, E. Teofilo, J. Gerstoft, C. Buendia et al., Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral???Naive HIV???Infected Adults, Clinical Infectious Diseases, vol.39, issue.7, pp.1038-1046, 2004.
DOI : 10.1086/424009

K. Squires, A. Lazzarin, J. Gatell, W. Powderly, V. Pokrovskiy et al., Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIV, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.36, issue.5, pp.1011-1019, 2004.
DOI : 10.1097/00126334-200408150-00003

M. Markowitz, C. Hill-zabala, J. Lang, E. Dejesus, Q. Liao et al., Induction With Abacavir/Lamivudine/Zidovudine Plus Efavirenz for 48 Weeks Followed by 48-Week Maintenance With Abacavir/Lamivudine/Zidovudine Alone in Antiretroviral-Naive HIV-1-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.39, issue.3, pp.257-264, 2005.
DOI : 10.1097/01.qai.0000169664.15536.20

N. Sosa, C. Hill-zabala, E. Dejesus, G. Herrera, F. A. Watson et al., Abacavir and Lamivudine Fixed-Dose Combination Tablet Once Daily Compared With Abacavir and Lamivudine Twice Daily in HIV-Infected Patients Over 48 Weeks (ESS30008, SEAL), JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.40, issue.4, pp.422-427, 2005.
DOI : 10.1097/01.qai.0000184859.24071.bd

M. Johnson, B. Grinsztejn, C. Rodriguez, J. Coco, E. Dejesus et al., Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures, AIDS, vol.19, issue.7, pp.685-694, 2005.
DOI : 10.1097/01.aids.0000166091.39317.99

G. Moyle, E. Dejesus, P. Cahn, S. Castillo, H. Zhao et al., Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.38, issue.4, pp.417-425, 2005.
DOI : 10.1097/01.qai.0000147521.34369.c9

A. Bonjoch, R. Paredes, J. Galvez, C. Miralles, S. Videla et al., Antiretroviral treatment simplification with 3

J. Gallant, E. Dejesus, J. Arribas, A. Pozniak, B. Gazzard et al., Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV, Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV, pp.251-260, 2006.
DOI : 10.1056/NEJMoa051871

L. Henanff, A. Giraudeau, B. Baron, G. Ravaud, and P. , Quality of Reporting of Noninferiority and Equivalence Randomized Trials, JAMA, vol.295, issue.10, pp.1147-1151, 2006.
DOI : 10.1001/jama.295.10.1147

C. Dunnett and M. Gent, Significance Testing to Establish Equivalence between Treatments, with Special Reference to Data in the Form of 2 x 2 Tables, Biometrics, vol.33, issue.4, pp.593-602, 1977.
DOI : 10.2307/2529457

C. Dunnett and M. Gent, An alternative to the use of two-sided tests in clinical trials, pp.1729-1738, 1996.

S. Snapinn, Noninferiority trials, Current Controlled Trials in Cardiovascular Medicine, vol.1, issue.1, pp.19-21, 2000.
DOI : 10.1186/CVM-1-1-019

D. Altman, K. Schulz, D. Moher, M. Egger, F. Davidoff et al., The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration, Annals of Internal Medicine, vol.134, issue.8
DOI : 10.7326/0003-4819-134-8-200104170-00012